News releases

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24-29 at McCormick Place Convention Center in Chicago, Illinois. Th...

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, "Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program," hosted by D. Boral Capital on September 30, 2025, at 10:00 ...

Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Enlivex"), a clinical-stage mac...

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS". The patent will provide Enlivex with added intellectual property protection in Isr...

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-re...